Ed­i­tas and Cel­gene sub Juno are tack­ling hottest im­munother­a­py cells

As the first CRISPR-edit­ed can­cer pa­tients watch their treat­ments un­fold, one of the first CRISPR com­pa­nies is re­jig­ging a ma­jor on­col­o­gy deal.

Ed­i­tas Med­i­cine is amend­ing its long-run­ning col­lab­o­ra­tion with Cel­gene and their sub­sidiary Juno Ther­a­peu­tics. The new deal will ex­pand the fo­cus of their work to cov­er a sub­set of im­mune cells that have be­come an in­creas­ing­ly hot tar­get for im­munother­a­py: gam­ma-delta cells.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.